A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2011
12/06/2011	US8071333 Anti-integrin antibodies, compositions, methods and uses
12/06/2011	US8071110 Activatable clostridial toxins
12/06/2011	US8071096 Anti-C5aR antibodies and uses thereof
12/06/2011	CA2600570C Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors
12/06/2011	CA2491317C Modafinil pharmaceutical compositions
12/06/2011	CA2489271C Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
12/06/2011	CA2485351C Cyanoguanidine prodrugs
12/06/2011	CA2483662C Heterocyclic derivatives as opioid receptor modulators
12/06/2011	CA2461033C Coniosulphides and their derivatives, processes for preparing them, and their use as pharmaceuticals
12/06/2011	CA2404736C Process for producing amine derivatives
12/06/2011	CA2383522C Neurotherapeutic composition and method
12/06/2011	CA2202087C Cloning and characterizing of genes associated with long-term memory
12/01/2011	WO2011150347A2 Non-peptide bdnf neurotrophin mimetics
12/01/2011	WO2011150281A2 A compositon for neurological or autoimmune diseases
12/01/2011	WO2011150229A2 Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
12/01/2011	WO2011150183A1 Radiolabeled compounds and methods thereof
12/01/2011	WO2011150175A2 Compositions and methods for pain reduction
12/01/2011	WO2011150160A2 Method of preventing and treating inflammatory diseases and disorders with abscisic acid
12/01/2011	WO2011150156A2 Heteroaryl compounds and methods of use thereof
12/01/2011	WO2011150098A1 Compositions and methods for reduction of mercury toxicity
12/01/2011	WO2011150017A1 Use of terilfunomide for maintaining fatigue level of a patient having multiple sclerosis
12/01/2011	WO2011150014A1 Use of teriflunomide for treating brain atrophy
12/01/2011	WO2011149862A1 Nicotinic receptor non-competitive antagonists modulators
12/01/2011	WO2011149859A1 Nicotinic receptor non-competitive antagonists
12/01/2011	WO2011149601A1 Treatment of vagally- mediated spectrum disorders with 5ht3 antagonists
12/01/2011	WO2011149461A1 Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
12/01/2011	WO2011149354A1 Mirnas involved in the blood brain barrier function
12/01/2011	WO2011149011A1 Novel indazole derivative or salt thereof, manufacturing intermediate therefor, antioxidant using same, and use for an indazole derivative or salt thereof
12/01/2011	WO2011148972A1 Pharmaceutical composition containing biologically active peptide
12/01/2011	WO2011148208A1 8-hydroxy-quinoline derivatives
12/01/2011	WO2011148203A1 Formulation based on sulpiride and a synergistic homeopathic composition for treatment of depressive syndrome
12/01/2011	WO2011148200A1 Treatment of pain
12/01/2011	WO2011147999A1 Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses
12/01/2011	WO2011147910A1 Pyrazole compounds as sigma receptor inhibitors
12/01/2011	WO2011147889A1 Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
12/01/2011	WO2011147780A1 Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
12/01/2011	WO2011147772A1 Ccr2 receptor antagonists
12/01/2011	WO2011147588A1 Compositions for use in genetic disorders comprising 4-phenyl- butyric acid and its salts
12/01/2011	WO2011147587A1 Compositions for use in cardiovascular diseases comprising 4 - phenyl - butyric acid and its salts
12/01/2011	WO2011147586A1 Compositions for use in neurological or neurodegenerative diseases with a genetic disorder background comprising 4-phenyl-butyric acid and its salts
12/01/2011	WO2011147584A1 Compositions for use in genetic disorders causative for cystic fibrosis comprising 4-phenyl-butyric acid and its salts
12/01/2011	WO2011147528A1 Biguanide compounds and its use for treating cancer
12/01/2011	WO2011147319A1 Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases
12/01/2011	WO2011147086A1 Microvesicles carrying small interfering rnas, preparation methods and uses thereof
12/01/2011	WO2011147025A1 Controlled release dosage form comprising quetiapine
12/01/2011	WO2011126385A3 Assay system
12/01/2011	WO2011097336A3 Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor
12/01/2011	WO2011091213A3 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
12/01/2011	WO2011090270A3 Composition containing osmotin for preventing and treating neurological disorders
12/01/2011	WO2011079213A9 Treating critically ill patients with intravenous ibuprofen
12/01/2011	WO2011077406A3 Process for preparing tablets comprising 5- hydroxytryptophan and tryptophan
12/01/2011	US20110294902 Pharmaceutical compositions providing enhanced drug concentrations
12/01/2011	US20110294889 Infusion and Injection Solution of Levodopa
12/01/2011	US20110294887 Controlled-release solution formulations of pregabalin
12/01/2011	US20110294886 Controlled-release tablet formulations of pregabalin
12/01/2011	US20110294885 Controlled-release pregabalin compositions
12/01/2011	US20110294883 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
12/01/2011	US20110294879 Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
12/01/2011	US20110294878 Inhibitors of Dimethylarginine Dimethylaminohydrolase
12/01/2011	US20110294870 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
12/01/2011	US20110294868 Modulation of transthyretin expression
12/01/2011	US20110294866 Pharmaceutical composition for treating dementia comprising shrna inhibiting s100a9 expression
12/01/2011	US20110294865 Methods of detecting a fragment of neurosecretory protein vgf for diagnosing alzheimer's disease
12/01/2011	US20110294859 Substituted pyridoxine-lactam carboxylate salts
12/01/2011	US20110294858 Substituted 6-methylnicotinamides as mglur5 positive allosteric modulators
12/01/2011	US20110294857 Inhibitor of casein kinase 1delta and casein kinase 1epsilon
12/01/2011	US20110294856 Novel oxadiazole derivatives and their medical use
12/01/2011	US20110294854 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
12/01/2011	US20110294850 Indoline derivatives
12/01/2011	US20110294848 Small molecule inhibitors of botulinum neurotoxins
12/01/2011	US20110294847 Novel Polymorphs Of Azabicyclohexane
12/01/2011	US20110294835 Muscarinic Agonists as Cognitive Enhancers
12/01/2011	US20110294834 Alkyl-substituted pyrazolopyrimidines
12/01/2011	US20110294833 Methods for Healthy Aging
12/01/2011	US20110294826 Pyrrolo[2,3-d]pyrimidine compounds
12/01/2011	US20110294825 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/01/2011	US20110294824 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/01/2011	US20110294823 Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds
12/01/2011	US20110294822 Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof
12/01/2011	US20110294821 5-ht1a receptor subtype agonist
12/01/2011	US20110294818 1h-quinazoline-2,4-diones
12/01/2011	US20110294817 N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine d3 receptor
12/01/2011	US20110294809 Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betahsd1
12/01/2011	US20110294808 Indazole Compounds As CCR1 Receptor Antagonists
12/01/2011	US20110294805 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof
12/01/2011	US20110294804 Novel bicyclic heterocyclic compound
12/01/2011	US20110294803 Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
12/01/2011	US20110294799 Organic Compounds
12/01/2011	US20110294797 Reverse-turn mimetics and method relating thereto
12/01/2011	US20110294795 Methods of synthesis and/or purification of diaminophenothiazinium compounds
12/01/2011	US20110294794 Treatment of proteinopathies using a farnesyl transferase inhibitor
12/01/2011	US20110294792 Purine derivatives as kinase inhibitors
12/01/2011	US20110294790 Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
12/01/2011	US20110294789 Compounds for rho kinase inhibition and for improving learning and memory
12/01/2011	US20110294788 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
12/01/2011	US20110294787 Substituted thiomorpholine derivatives
12/01/2011	US20110294786 Substituted bicyclic pyrimidone derivatives
12/01/2011	US20110294784 Gamma secretase modulators
12/01/2011	US20110294782 Small molecule pak inhibitors
12/01/2011	US20110294781 Pyrazolo-pyrimidine compounds

1 ... 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 ... 1833